The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Clostridium Difficile-Associated Diarrhea and Colitis
Abstract
Objectives: To review and summarize the status of diagnosis, epidemiology, infection control, and treatment of Clostridium difficile -associated disease (CDAD). Diagnosis: A case definition of CDAD should include the presence of symptoms (usually diarrhea) and at least one of the following positive tests: endoscopy revealing pseudomembranes, stool cytotoxicity test for toxin B, stool enzyme immunoassay for toxin A or B, or stool culture for C difficile (preferably with confirmation of organism toxicity if a direct stool toxin test is negative or not done). Testing of asymptomatic patients, including those who are asymptomatic after treatment, is not recommended other than for epidemiologic purposes. Lower gastrointestinal endoscopy is the only diagnostic test for pseudomembranous colitis, but it is expensive, invasive, and insensitive (51% to 55%) for the diagnosis of CDAD. Stool culture is the most sensitive laboratory test currently in clinical use, but it is not as specific as the cell cytotoxicity assay. Epidemiology: C difficile is the most frequently identified cause of nosocomial diarrhea. The majority of C difficile infections are acquired nosocomially, and most patients remain asymptomatic following acquisition. Antimicrobial exposure is the greatest risk factor for patients, especially clindamycin, cephalosporins, and penicillins, although virtually every antimicrobial has been implicated. Cases of CDAD unassociated with prior antimicrobial or antineoplastic use are very rare. Hands of personnel, as well as a variety of environmental sites within institutions, have been found to be contaminated with C difficile , which can persist as spores for many months. Contaminated commodes, bathing tubs, and electronic thermometers have been implicated as sources of C difficile . Symptomatic and asymptomatic infected patients are the major reservoirs and sources for environmental contamination. Both genotypic and phenotypic typing systems for C difficile are available and have enhanced epidemiologic investigation greatly. Infection Control: Successful infection control measures designed to prevent horizontal transmission include the use of gloves in handling body substances and replacement of electronic thermometers with disposable devices. Isolation, cohorting, handwashing, environmental disinfection, and treatment of asymptomatic carriers are recommended practices for which convincing data of efficacy are not available. The most successful control measure directed at reduction in symptomatic disease has been antimicrobial restriction. Treatment: Treatment of symptomatic (but not asymptomatic) patients with metronidazole or vancomycin for 10 days is effective; metronidazole may be preferred to reduce risk of vancomycin resistance among other organisms in hospitals. Recurrence of symptoms occurs in 7% to 20% of patients and is due to both relapse and reinfection. Over 90% of first recurrences can be treated successfully in the same manner as initial cases. Combination treatment with vancomycin plus rifampin or the addition orally of the yeast Saccharomyces boulardii to vancomycin or metronidazole treatment has been shown to prevent subsequent diarrhea in patients with recurrent disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia
Bartlett, J. G., Chang, T. W., Gurwith, M., Gorbach, S. L., & Onderdonk, A. B. (1978) · New England Journal of Medicine · doi:10.1056/nejm197803092981003 · Cited by 1,374
Nosocomial Acquisition of Clostridium difficile Infection
McFarland, L. V., Mulligan, M. E., Kwok, R. Y. Y., & Stamm, W. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198901263200402 · Cited by 1,326
Self-citationKelly, C. P., Pothoulakis, C., & LaMont, J. T. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401273300406 · Cited by 1,321
McFarland, L. V. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510480037031 · Cited by 857
Teasley, D., Olson, M., Gebhard, R., Gerding, D., Peterson, L., Schwartz, M., & Lee, J. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91036-x · Cited by 785
Self-citationHALL, I. C. (1935) · American Journal of Diseases of Children · doi:10.1001/archpedi.1935.01970020105010 · Cited by 772
CLOSTRIDIUM DIFFICILE AND THE ÆTIOLOGY OF PSEUDOMEMBRANOUS COLITIS
Larson, H. E., Price, A. B., Honour, P., & Borriello, S. P. (1978) · The Lancet · doi:10.1016/s0140-6736(78)90912-1 · Cited by 652
Selective and differential medium for isolation of Clostridium difficile
George, W. L., Sutter, V. L., Citron, D., & Finegold, S. M. (1979) · Journal of Clinical Microbiology · doi:10.1128/jcm.9.2.214-219.1979 · Cited by 632
Clindamycin-Associated Colitis: A Prospective Study
TEDESCO, F. J., BARTON, R. W., & ALPERS, D. H. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-81-4-429 · Cited by 606
Clostridium difficile: its disease and toxins
Lyerly, D. M., Krivan, H. C., & Wilkins, T. D. (1988) · Clinical Microbiology Reviews · doi:10.1128/cmr.1.1.1 · Cited by 576
Cited by
Siegel, J. D., Rhinehart, E., Jackson, M., & Chiarello, L. (2007) · American Journal of Infection Control · doi:10.1016/j.ajic.2007.10.007 · Cited by 3,456
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Self-citationAn Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Self-citationTomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J. R., Young, J.-A. H., & Boeckh, M. A. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.06.019 · Cited by 1,797
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Clostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313
Management of multidrug-resistant organisms in health care settings, 2006
Siegel, J. D., Rhinehart, E., Jackson, M., & Chiarello, L. (2007) · American Journal of Infection Control · doi:10.1016/j.ajic.2007.10.006 · Cited by 1,283
Antibiotic-Associated Diarrhea
Bartlett, J. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp011603 · Cited by 1,197
Pepin, J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041104 · Cited by 1,128
Practice Guidelines for the Management of Infectious Diarrhea
Guerrant, R. L., Van Gilder, T., Steiner, T. S., Thielman, N. M., Slutsker, L., Tauxe, R. V., Hennessy, T., Griffin, P. M., DuPont, H., Bradley Sack, R., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/318514 · Cited by 1,074
Pepin, J., Saheb, N., Coulombe, M.-A., Alary, M.-E., Corriveau, M.-P., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/496986 · Cited by 995
Asymptomatic Carriage of Clostridium difficile and Serum Levels of IgG Antibody against Toxin A
Kyne, L., Warny, M., Qamar, A., & Kelly, C. P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420604 · Cited by 935
Clostridium difficile Infection in Patients Discharged from US Short-stay Hospitals, 1996–20031
McDonald, L. C., Owings, M., & Jernigan, D. B. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1203.051064 · Cited by 788
O’Grady, N. P., Barie, P. S., Bartlett, J. G., Bleck, T., Carroll, K., Kalil, A. C., Linden, P., Maki, D. G., Nierman, D., Pasculle, W., et al. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e318169eda9 · Cited by 600
Narrative Review: The New Epidemic of Clostridium difficile–Associated Enteric Disease
Bartlett, J. G. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-10-200611210-00008 · Cited by 599
Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era
Polage, C. R., Gyorke, C. E., Kennedy, M. A., Leslie, J. L., Chin, D. L., Wang, S., Nguyen, H. H., Huang, B., Tang, Y.-W., Lee, L. W., et al. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.4114 · Cited by 593
Increasing Risk of Relapse after Treatment of Clostridium difficile Colitis in Quebec, Canada
Pepin, J., Alary, M.-E., Valiquette, L., Raiche, E., Ruel, J., Fulop, K., Godin, D., & Bourassa, C. (2005) · Clinical Infectious Diseases · doi:10.1086/430315 · Cited by 570
Safdar, N., & Maki, D. G. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-11-200206040-00013 · Cited by 556
Riggs, M. M., Sethi, A. K., Zabarsky, T. F., Eckstein, E. C., Jump, R. L. P., & Donskey, C. J. (2007) · Clinical Infectious Diseases · doi:10.1086/521854 · Cited by 550
Surawicz, C. M., McFarland, L. V., Greenberg, R. N., Rubin, M., Fekety, R., Mulligan, M. E., Garcia, R. J., Brandmarker, S., Bowen, K., Borjal, D., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/318130 · Cited by 529
Self-citationClinical Recognition and Diagnosis of Clostridium difficile Infection
Bartlett, J. G., & Gerding, D. N. (2008) · Clinical Infectious Diseases · doi:10.1086/521863 · Cited by 527
Self-citationAas, J., Gessert, C. E., & Bakken, J. S. (2003) · Clinical Infectious Diseases · doi:10.1086/367657 · Cited by 518
Clostridium difficile-associated diarrhea in adults
Poutanen, S. M. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1031189 · Cited by 410
Johnson, S., Samore, M. H., Farrow, K. A., Killgore, G. E., Tenover, F. C., Lyras, D., Rood, J. I., DeGirolami, P., Baltch, A. L., Rafferty, M. E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911253412203 · Cited by 379
Self-citationPrevention and Treatment of Cancer-Related Infections
Baden, L. R., Bensinger, W., Angarone, M., Casper, C., Dubberke, E. R., Freifeld, A. G., Garzon, R., Greene, J. N., Greer, J. P., Ito, J. I., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0146 · Cited by 368
Treatment of Clostridium difficile-associated disease: old therapies and new strategies
Aslam, S., Hamill, R. J., & Musher, D. M. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70215-2 · Cited by 366
Antibiotic treatment for Clostridium difficile -associated diarrhoea in adults
Nelson, R. L., Suda, K. J., & Evans, C. T. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004610.pub5 · Cited by 366
Recurrent Clostridium Difficile Disease: Epidemiology and Clinical Characteristics
McFarland, L. V., Surawicz, C. M., Rubin, M., Fekety, R., Elmer, G. W., & Greenberg, R. N. (1999) · Infection Control & Hospital Epidemiology · doi:10.1086/501553 · Cited by 353
Clostridium difficile infection: epidemiology, risk factors and management
Ananthakrishnan, A. N. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.190 · Cited by 352
Clostridium difficile–Associated Diarrhea: A Review
Mylonakis, E., Ryan, E. T., & Calderwood, S. B. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.4.525 · Cited by 339
Valiquette, L., Cossette, B., Garant, M.-P., Diab, H., & Pépin, J. (2007) · Clinical Infectious Diseases · doi:10.1086/519258 · Cited by 330
O'Brien, J. A., Lahue, B. J., Caro, J. J., & Davidson, D. M. (2007) · Infection Control & Hospital Epidemiology · doi:10.1086/522676 · Cited by 315
Measures to Control and Prevent Clostridium difficile Infection
Gerding, D. N., Muto, C. A., & Owens, Jr. (2008) · Clinical Infectious Diseases · doi:10.1086/521861 · Cited by 311
Self-citationEpidemiology, Risk Factors and Treatments for Antibiotic-Associated Diarrhea
McFarland, L. V. (1998) · Digestive Diseases · doi:10.1159/000016879 · Cited by 310
Bliss, D. Z., Johnson, S., Savik, K., Clabots, C. R., Willard, K., & Gerding, D. N. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-12-199812150-00004 · Cited by 298
Self-citationSethi, A. K., Al-Nassir, W. N., Nerandzic, M. M., Bobulsky, G. S., & Donskey, C. J. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/649016 · Cited by 289
Treatment of Clostridium difficile Infection
Gerding, D. N., Muto, C. A., & Owens, Jr. (2008) · Clinical Infectious Diseases · doi:10.1086/521860 · Cited by 287
Self-citationYokoe, D. S., Mermel, L. A., Anderson, D. J., Arias, K. M., Burstin, H., Calfee, D. P., Coffin, S. E., Dubberke, E. R., Fraser, V., Gerding, D. N., et al. (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591060 · Cited by 280
Self-citationClostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea
Sougioultzis, S., Kyne, L., Drudy, D., Keates, S., Maroo, S., Pothoulakis, C., Giannasca, P. J., Lee, C. K., Warny, M., Monath, T. P., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.004 · Cited by 260
Clostridium difficile and inflammatory bowel disease
Issa, M., Ananthakrishnan, A. N., & Binion, D. G. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20500 · Cited by 257
Clostridium difficile – From Colonization to Infection
Schäffler, H., & Breitrück, A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00646 · Cited by 174
Mora, A. L., Salazar, M., Pablo-Caeiro, J., Frost, C. P., Yadav, Y., DuPont, H. L., & Garey, K. W. (2012) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31822f42eb · Cited by 59
Metadata
- Authors
- Gerding, D. N., Johnson, S., Peterson, L. R., Mulligan, M. E., & Silva, J.
- Venue
- Infection Control & Hospital Epidemiology
- Publisher
- Cambridge University Press (CUP)
- Published
- 1995-08
- Volume
- 16
- Issue
- 8
- Pages
- 459-477
- ISSN
- 0899-823X (ISSN-L)
- 1559-6834
- OpenAlex
- W2153996209
- Cited by
- 631
- References
- 126
- FWCI
- 10.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.